Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
polycythemia vera
ruxolitinib
tuberculosis peritonitis
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
02
2020
accepted:
31
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks for opportunistic infection, such as mycobacterium tuberculosis (MTB) infection, and reactivation of occult viral infection. Herein, we report the case of a 76-year-old male with PV who developed tuberculosis peritonitis under ruxolitinib therapy for 28 weeks. While previous studies and case reports have suggested an increased risk of MTB infection of various organs during ruxolitinib treatment of MPNs, this case is apparently the first of tuberculosis peritonitis in a patient with MPN treated with ruxolitinib. A review of previous case reports suggests the need for careful observation for MTB from the relatively early phase of ruxolitinib treatment, given that the median duration from the start of ruxolitinib treatment to the emergence of MTB was 20 weeks (range: 3-88 weeks). Clinicians should consider tuberculosis peritonitis as a differential diagnosis when patients with MPN treated with ruxolitinib develop infectious abdominal symptoms.
Identifiants
pubmed: 32308443
doi: 10.2147/IDR.S249030
pii: 249030
pmc: PMC7152536
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1017-1021Informations de copyright
© 2020 Sakiyama et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Leukemia. 2014 Aug;28(8):1750-1
pubmed: 24625550
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):18-23
pubmed: 31699655
BMJ Case Rep. 2014 Jun 02;2014:
pubmed: 24891492
Infection. 2013 Dec;41(6):1089-95
pubmed: 23943073
Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694
pubmed: 30965140
Cancer Res. 2015 Jun 1;75(11):2187-99
pubmed: 25832652
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
BMC Res Notes. 2012 Oct 05;5:552
pubmed: 23039051
Case Rep Infect Dis. 2015;2015:284168
pubmed: 26788384
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Protein Sci. 2018 Dec;27(12):1984-2009
pubmed: 30267440
Gastrointest Endosc Clin N Am. 2001 Jan;11(1):79-91
pubmed: 11175976
Leuk Lymphoma. 2015 May;56(5):1528-9
pubmed: 25213182
J Clin Gastroenterol. 2006 Sep;40(8):705-10
pubmed: 16940883
N Engl J Med. 2013 Jul 11;369(2):197-8
pubmed: 23841743
N Engl J Med. 2013 Aug 15;369(7):681-3
pubmed: 23944322
Tubercle. 1990 Jun;71(2):121-6
pubmed: 2219461
Aliment Pharmacol Ther. 2005 Oct 15;22(8):685-700
pubmed: 16197489
Haematologica. 2015 Sep;100(9):1139-45
pubmed: 26069290
Am J Hematol. 2018 Mar;93(3):339-347
pubmed: 29150886
Intern Med. 2018 May 1;57(9):1297-1300
pubmed: 29279479
N Engl J Med. 2013 Jan 10;368(2):161-70
pubmed: 23301733
Int J Infect Dis. 2019 Mar;80:134-136
pubmed: 30639623
Ann Hematol. 2015 Mar;94(3):519-20
pubmed: 25172457
Blood. 2013 Aug 15;122(7):1192-202
pubmed: 23770777
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Haematologica. 2014 Feb;99(2):292-8
pubmed: 23911705
Nat Rev Drug Discov. 2011 Feb;10(2):127-40
pubmed: 21283107
Leukemia. 2019 Apr;33(4):844-862
pubmed: 30700842
Leukemia. 2014 Jan;28(1):225-7
pubmed: 23929216
J Clin Transl Hepatol. 2019 Jun 28;7(2):140-148
pubmed: 31293914
Case Rep Hematol. 2016;2016:2389038
pubmed: 27843657
Chest. 2013 May;143(5):1478-1479
pubmed: 23648912
Ann Hematol. 2016 Jun;95(7):1207-9
pubmed: 27113251